Literature DB >> 15355313

The effect of PARP inhibitor on ischaemic cell death, its related inflammation and survival signals.

Seong-Ho Koh1, Younjoo Park, Chi Won Song, Jun Gyou Kim, Kisok Kim, Juhan Kim, Myung-Ho Kim, Seung Ro Lee, Dong Won Kim, Hyun-Jeung Yu, Dae-Il Chang, Se Jin Hwang, Seung Hyun Kim.   

Abstract

Poly(ADP-ribose) polymerase (PARP) plays an important role in ischaemic cell death, and 3-aminobenzamide (3-AB), one of the PARP inhibitors, has a protective effect on ischaemic stroke. We investigated the neuroprotective mechanisms of 3-AB in ischaemic stroke. The occlusion of middle cerebral artery (MCA) was made in 170 Sprague-Dawley rats, and reperfusion was performed 2 h after the occlusion. Another 10 Sprague-Dawley rats were used for sham operation. 3-AB was administered to 85 rats 10 min before the occlusion [3-AB group (n = 85) vs. control group without 3-AB (n = 85)]. Infarct volume and water content were measured, brain magnetic resonance imaging, terminal deoxynucleotidyltransferase (TdT)-mediated dUTP-biotin nick end-labelling (TUNEL) and Cresyl violet staining were performed, and immunoreactivities (IRs) of poly(ADP-ribose) polymer (PAR), cleaved caspase-3, CD11b, intercellular adhesion molecule-1 (ICAM-1), cyclooxygenase-2 (COX-2), phospho-Akt (pAkt) and phospho-glycogen synthase kinase-3 (pGSK-3) were compared in the peri-infarcted region of the 3-AB group and its corresponding ischaemic region of the control group at 2, 8, 24 and 72 h after the occlusion. In the 3-AB group, the infarct volume and the water content were decreased (about 45% and 3.6%, respectively, at 24 h), the number of TUNEL-positive cells was decreased (about 36% at 24 h), and the IRs of PAR, cleaved caspase-3, CD11b, ICAM-1 and COX-2 were significantly reduced, while the IRs of pAkt and pGSK-3 were increased. These results suggest that 3-AB treatment could reduce the infarct volume by reducing ischaemic cell death, its related inflammation and increasing survival signals. The inhibition of PARP could be another potential neuroprotective strategy in ischaemic stroke.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15355313     DOI: 10.1111/j.1460-9568.2004.03632.x

Source DB:  PubMed          Journal:  Eur J Neurosci        ISSN: 0953-816X            Impact factor:   3.386


  32 in total

Review 1.  Parthanatos: mitochondrial-linked mechanisms and therapeutic opportunities.

Authors:  Amos A Fatokun; Valina L Dawson; Ted M Dawson
Journal:  Br J Pharmacol       Date:  2014-04       Impact factor: 8.739

Review 2.  The inflammatory response in stroke.

Authors:  Qing Wang; Xian Nan Tang; Midori A Yenari
Journal:  J Neuroimmunol       Date:  2006-12-26       Impact factor: 3.478

Review 3.  Inflammatory responses in brain ischemia.

Authors:  Masahito Kawabori; Midori A Yenari
Journal:  Curr Med Chem       Date:  2015       Impact factor: 4.530

Review 4.  Role of glycogen synthase kinase-3beta in cardioprotection.

Authors:  Magdalena Juhaszova; Dmitry B Zorov; Yael Yaniv; H Bradley Nuss; Su Wang; Steven J Sollott
Journal:  Circ Res       Date:  2009-06-05       Impact factor: 17.367

5.  Thioredoxin-interacting protein mediates nuclear-to-plasma membrane communication: role in vascular endothelial growth factor 2 signaling.

Authors:  Oded N Spindel; Chen Yan; Bradford C Berk
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-02-16       Impact factor: 8.311

6.  Long-lasting neuroprotection and neurological improvement in stroke models with new, potent and brain permeable inhibitors of poly(ADP-ribose) polymerase.

Authors:  F Moroni; A Cozzi; A Chiarugi; L Formentini; E Camaioni; D E Pellegrini-Giampietro; Y Chen; S Liang; M M Zaleska; C Gonzales; A Wood; R Pellicciari
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

7.  Poly(ADP-ribose) polymerase 1 promotes oxidative-stress-induced liver cell death via suppressing farnesoid X receptor α.

Authors:  Cheng Wang; Fengxiao Zhang; Lin Wang; Yanqing Zhang; Xiangrao Li; Kun Huang; Meng Du; Fangmei Liu; Shizheng Huang; Youfei Guan; Dan Huang; Kai Huang
Journal:  Mol Cell Biol       Date:  2013-09-16       Impact factor: 4.272

Review 8.  Therapeutic applications of PARP inhibitors: anticancer therapy and beyond.

Authors:  Nicola J Curtin; Csaba Szabo
Journal:  Mol Aspects Med       Date:  2013-01-29

Review 9.  Drug targets for traumatic brain injury from poly(ADP-ribose)polymerase pathway modulation.

Authors:  Valerie C Besson
Journal:  Br J Pharmacol       Date:  2009-04-09       Impact factor: 8.739

10.  Differential PARP cleavage: an indication of heterogeneous forms of cell death and involvement of multiple proteases in the infarct of focal cerebral ischemia in rat.

Authors:  Ganta Vijay Chaitanya; Phanithi Prakash Babu
Journal:  Cell Mol Neurobiol       Date:  2009-02-19       Impact factor: 5.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.